Conference Description

This course is filled and registration is closed!

October 18, 2008
Doubletree Birmingham
808 20th Street South
Birmingham, AL 35205
(205) 933-9000

Tell a friend about this conference

Release Date: October 18, 2008

Expiration Date: October 18, 2008

Estimated Time To Complete CME Activity: 7.5 Hours

Medium/Method: Live Conference

Hardware/Software Requirements: None

CME Credits: 13.25*

Nonrefundable registration fee: $0.

Target Audience: Physicians, Nurse Practitioners, and Physician Assistants.

Program Summary:
This educational activity is designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about TIA and CVA risk reduction, Restless Leg Syndrome, Incretins and Incretin-Mimetics and Insulin Therapy in Diabetes, Rheumatoid Arthritis, Fibromyalgia, Contraception, Osteoporosis, and Chronic Pain Management. In planning this CME activity, the National Association for Continuing Education (NACE) performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Learning objectives (see below), linked to identified gaps, were developed and will be addressed by each presenter. This multidisciplinary program will utilize a variety of educational techniques incorporating the various aspects of Adult Learning Principles. There will be emphasis on audience participation utilizing interactive case-based presentations to deliver educational material. Participants will be asked to engage in pre and post testing to collect data for outcome studies and to uncover unmet needs for future programming. Each participant will be provided with a syllabus containing presentations, clinical tools, and practical guidelines at the start of the program to be used for future reference.

Learning Objectives:
At the conclusion of this program, participants should be able to:

1. More readily identify an acute ischemic stroke; Utilize current management strategies to improve outcomes; Recognize the most effective treatments for secondary prevention
2. Discuss the efficacy, utilization, and continuation rates of the various methods of contraception currently in use; Recognize the benefits and risks associated with the various forms of contraception; Explain the rationale for changing the traditional 21/7-day regimen of oral contraceptives
3. Discuss new treatments for type 2 Diabetes including incretin-mimetics, DPP-IV inhibitors, and incretin analogs; Compare and contrast newer therapies with traditional antidiabetic agents; Discuss the place of newer agents in the overall management strategy for patients with Diabetes
4. Explain the natural progression to relative insulin deficiency in patients with type 2 Diabetes; Recognize when to initiate insulin therapy and how to overcome barriers to do so; Identify methods of optimizing glycemic control in patients with type 2 Diabetes with the use of insulin; Explain risks and discuss approaches for minimizing risk of hypoglycemia and weight gain
5. Utilize a pain assessment tool for initial assessment and chronic monitoring during pain management; Choose stratified pharmacotherapy for diabetic peripheral neuropathic pain, osteoarthritis pain and low back pain
6. Recognize barriers to effective management of osteoporosis; More effectively utilize nonpharmacologic therapies (Calcium and Vitamin D) to decrease fragility fractures; Discuss the risks and benefits of various compounds available to individualize therapy
7. Recognize criteria for accurate diagnosis of fibromyalgia established by the American College of Rheumatology; Describe patient demographics and associated features in fibromyalgia; Describe differential diagnosis and basic testing to aid in excluding other conditions; Understand the role of non-pharmacologic and pharma cologic treatment options; Recognize the role of analgesics like tramadol, and non-opioid pain modulating agents such as pramipexole, pregabalin, and duloxetine; Describe emerging therapeutic options on the horizon for fibromyalgia
8. Define criteria for the diagnosis of RA; Outline potential benefits of early diagnosis and aggressive management; Describe why the TNF inhibitors and newer biologics can potentially improve outcomes and summarize their efficacy and safety
9. List the four cardinal features of RLS; Name the category of pharmaceutical agents which is first line treatment for RLS; Define and treat augmentation

Agenda:

7:15-7:45 am		Continental Breakfast and Registration
7:45-8:00		Welcome Remarks Jack Kravitz, MD
8:00-8:50		Restless Leg Syndrome: Optimizing Treatment from a Patient Centered Approach Barbara Phillips, MD
8:50-9:40		Stroke Neuromythology Cafe' Michael Sloan, MD
9:40-10:30		Contraception-Circa 2008 Murray A. Freedman, MS, MD
10:30-10:50		Break
10:50-11:40		Incretins and Incretin-Mimetics: The Role in Diabetes Christopher Newton, MD
11:40-12:30		Diabetes Mellitus – Case Studies in Insulin Therapy Christopher Newton, MD
12:30-1:30		Lunch
1:30-2:20		Case Studies in Chronic Pain Management Louis Kuritzky, MD
2:20-3:10		Osteoporosis: Individualizing Therapy Louis Kuritzky, MD
3:10-3:30		Break
3:30-4:20		Understanding Fibromyalgia – Biology and Therapy Jefrey Lieberman, MD
4:20-5:10		Rheumatoid Arthritis – Early Diagnosis and Effective Management Jefrey Lieberman, MD

Faculty:
Murray A. Freedman, MS, MD
Clinical Professor
Department of Obstetrics and Gynecology
Medical College of Georgia
Augusta, GA

Louis Kuitzky, MD
Clinical Assistant Professor
Department of Community Health & Family Medicine
University of Florida
Gainseville, FL

Jefrey Lieberman, MD, FACP
Medical Director, Arthritis Care Center, Dekalb Medical Center
Clinical Associate, Emory University College of Medicine
Atlanta, GA

Christopher Alan Newton, MD
Division of Endocrinology
Department of Internal Medicine
Emory University School of Medicine
Atlanta, GA

Barbara Phillips, MD, MSPH, FCCP
Professor of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
University of Kentucky College of Medicine
Lexington, KY

Michael Allan Sloan, MD
Professor and Director
TGH/USF Stroke Program
Department of Neurology University of South Florida College of Medicine
Tampa, FL

Program Chair: Gregg Sherman, MD

Activity Director: Michelle Frisch, MPH

*Continuing Education Information
This activity has been reviewed and is acceptable for up to 13.25 Prescribed credit(s) by the American Academy of Family Physicians. Of these credits, 5.75 conform to the AAFP criteria for evidence-based CME clinical content. CME credit has been increased to reflect 2 for 1 credit for only the EB CME portion. When reporting AAFP credit, report total Prescribed and Elective credit for this activity. It is not necessary to label credit as evidence-based CME for reporting purposes.

The EB CME credit awarded for this activity was based on practice recommendations that were the most current with the strongest level of evidence available at the time this activity was approved. Since clinical research is ongoing, AAFP recommends that learners verify sources and review these and other recommendations prior to implementation into practice.

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Massachusetts Medical School designates this educational activity for a maximum of 7.5 AMA PRA Category I Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 9 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spend in the educational activity.

Policy on Faculty and Provider Disclosure: It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

This activity is supported by educational donations provided by: Amgen and Wyeth Pharmaceuticals, Amylin, Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Endo, Lilly, Novo nordisk, sanofi-aventis, Sepracor, UCB.